Virica Biotech

📣 We are going to be in Barcelona attending World Vaccine Congress Europe! Our expert Oliver Varette is attending and he’d love to chat! Are you looking to drive up viral vaccine manufacturing yield and drive down manufacturing COGS? Drop by our poster presentation: ✔Development and Scale-up Validation of Small Molecule Viral Sensitizers for Increased Vaccine Manufacturing Yields. Learn about how leveraging our Viral Sensitizers (VSEᵀᴹ) and Design of Experiments (DoE) powered workflows unlock: ✔ Rapid viral vector production optimization. ✔ Robust increase in viral vector yield and quality. ✔ Significant reduction in long-term manufacturing COGS. Connect with us through our website: https://lnkd.in/dZc63P3J Want a quick overview of our technology? https://lnkd.in/gu2m3RcX #biomanufacturing #innovation #WVC

📣 We’re thrilled to announce a new collaboration project with eXmoor Pharma, funded by a joint UK-Canada government initiative. This project aims to enhance the manufacturing of adeno-associated vectors (AAVs) crucial for gene therapies, ultimately reducing costs and improving the accessibility of life-saving therapies. 🔬 Key Highlights: ✔ Leveraging Virica’s Viral Sensitizers (VSE™) formulations to boost AAV yields. ✔ Expertise from eXmoor in optimizing the manufacture of vectors and scaling up to commercial levels. The collaboration underscores a shared commitment between the UK and Canada to leverage innovative technologies to tackle future healthcare challenges. 🔗 Link to Full PR: https://lnkd.in/d84tr5zZ 🔗 Learn more about us: eXmoor Pharma: https://lnkd.in/eARjGFwK Virica Biotech: https://lnkd.in/e3zvChi #biomanufactruing #innovation #AAV #UK #Canada

📣 We are attending ESGCT in Rome! We have the dream team Jondavid de Jong, Andrea Vervoort and Oliver Varette attending and they’d love to chat! Are you looking to drive up CGT manufacturing yield and drive down manufacturing COGS? Check out our 3 poster presentations: ✔ Harnessing the power of High-Throughput Virology and Design of Experiments for rapid vector production process optimization. Poster #P0832. Poster session IV Thursday, October 24th 18:00-19:30 CET ✔ Increasing AAV yield: High-Throughput screening of next-gen small molecule enhancers and process automation in cloud-connected bioreactors. Poster #P0203. Poster session I Tuesday, October 22nd19:30-21:00 CET ✔ Viral Sensitizers unleash host cell potential to enhance AAV production. Poster #P0811. Poster session III Thursday, October 24th 14:00-15:30 CET Learn about how leveraging our Viral Sensitizers (VSEᵀᴹ) and Design of Experiments (DoE) powered workflows unlock: ✔ Rapid viral vector production optimization. ✔ Robust increase in viral vector yield and quality. ✔ Significant reduction in long-term manufacturing COGS. 🤝Connect with us through our website: https://hubs.la/Q02T6gpf0 Want a quick overview of our technology? https://hubs.la/Q02T6jKm0 #biomanufacturing #innovation #ESGCT

🔬 It’s Friday! And we have a special announcement for today’s “Ask a Virologist”! Our host Keara Sutherland, will be speaking at our upcoming webinar on Optimizing AAV Production with Design of Experiments (DoE), hosted by BioInsights 📅 Date: November 20, 2024 ⏰ Time: 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET Keara will be discussing how Virica’s Viral Sensitizer (VSEᵀᴹ) platform and DoE workflows combined with Culture Biosciences cloud-connected bioreactors, can streamline AAV production, improve yields, and reduce timelines. ✔️Webinar Registration Link: https://hubs.ly/Q02S_SLT0 As you may know, Keara loves DoE and has talked about the power of DoE in a previous Ask the Virologist video! Link below in case you missed it: https://hubs.ly/Q02S_YwX0 Are you using DoE? Drop it in the comments below! 👉 If you find this series valuable subscribe to our newsletter for all things CGT! https://hubs.ly/Q02S__tM0 #biomanufacturing #innovation #QandAs #askavirologist

This week at #CGMesa24 Jean-Simon Diallo, CEO at Virica, met with Narendra Maheshri, VP, Genetic Medicines, Ginkgo Bioworks, Inc. to discuss our recent partnership announcement. This collaboration is expected to drive down manufacturing costs and make gene therapies more accessible, combining Ginkgo's cutting-edge screening capabilities with Virica's proprietary Viral Sensitizer (VSE) platform. Identify the best combination of VSEs to boost your AAV yield in as few as 6 weeks! Contact Ginkgo to learn about their AAV Services for Gene Therapies: https://lnkd.in/eakvPGcg Contact Virica to learn about how their cell enhancers can increase productivity: https://lnkd.in/e3zvChi #AAVproduction #cellandgenetherpies #viralvectors

📣 Looking to drive up CGT manufacturing productivity and drive down COGS? Our CEO Jean-Simon Diallo and CCO Beth Thompson - Webb are at Cell and Gene on the Mesa and would love to chat! 🤝 Meet with us or connect with us through partnering: https://lnkd.in/deKPvPXG Connect through our website: https://lnkd.in/dZajZX2V Curious about our technology? Here’s a brief overview: https://lnkd.in/gu2m3RcX #biomanufacturing #CGMesa #innovation

Join us for a Webinar on Optimizing AAV Production with Design of Experiments (DoE)! Hosted by BioInsights 📅 Date: November 20, 2024 ⏰ Time: 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET Learn how Virica Biotech's cell enhancers and Culture Biosciences cloud-connected bioreactors combined with DoE can streamline AAV gene therapy production. We’ve teamed up to show how Virica’s Viral Sensitizer (VSEᵀᴹ) platform and Culture Bio’s cloud-based bioreactors can improve productivity, shorten timelines, and ensure more efficient AAV production scale-up. Webinar topics include: 🔹 Identifying key challenges that impact AAV production 🔹 Virica’s High-Throughput Virology (HTVᵀᴹ) to identify optimal cell-enhancing compounds 🔹 How Culture’s cloud-connected bioreactor platform enables rapid evaluation of production parameters with transparent data transfer 🔹 Real-world data comparing the efficiency and yield improvements between DoE-based compound identification and traditional non-DoE methods Register now: https://hubs.la/Q02SqtCg0 #AAV #GeneTherapy #Biotech #Webinar #DoE #Biomanufacturing

📣 We are in sunny Arizona attending Cell and Gene on the Mesa! Meet with our CEO Jean-Simon Diallo and CCO Beth Thompson - Webb to learn about how leveraging our Viral Sensitizers (VSEᵀᴹ) and Design of Experiments (DoE) powered workflows unlock: ✔ Rapid viral vector production optimization. ✔ Robust increase in viral vector yield and quality. ✔ Significant reduction in long-term manufacturing COGS. 💡 Looking to unlock the potential of your CGT manufacturing platform? 🤝 Connect with us through partnering: https://lnkd.in/deKPvPXG Or through our website: https://lnkd.in/dZajZX2V Curious about our technology? Here’s a brief overview: https://lnkd.in/gu2m3RcX #biomanufacturing #innovation #CGMesa

🔬 It’s Friday, so that means we are back with another “Ask a Virologist”! Cell and gene (CGT) manufacturing is complex with many challenges and bottlenecks! 💡 Given the complexity, there is no “silver bullet” to tackle manufacturing bottlenecks. A winning strategy combines synergistic technologies for additive enhancement. This week Oliver Varette highlights what makes our Viral Sensitizers (VSEᵀᴹ) complementary and synergistic to other yield enhancement approaches. 👇 Check out the video to know more! Virica’s VSEs are cell enhancers that make host cells amenable to viral vector production, leading to robust improvements in yield and quality. ✔ VSEs possess unique modes of action: https://lnkd.in/dusFXNwK ✔ VSEs are broadly applicable to various virus and cell line combinations and applications: https://lnkd.in/dHxMEGtt ✔ They are non-disruptive to your production process and are rapidly metabolized from host cells: https://lnkd.in/dinpFQeJ 👉 If you find this series valuable subscribe to our newsletter for all things CGT! https://lnkd.in/d-rf3XVX #biomanufacturing #innovation #QandAs #askavirologist

📣 Virica Biotech and Ginkgo Bioworks, Inc. have announced a strategic partnership aimed at improving AAV gene therapy production. Virica will provide a panel of its Viral Sensitizer Enhancers (VSEᵀᴹ) to Ginkgo for high-throughput AAV production screening, while Ginkgo will utilize its advanced screening platform to test VSEs directly in clients' cell lines. This collaboration is expected to drive down manufacturing costs and make gene therapies more accessible, combining Ginkgo's cutting-edge screening capabilities with Virica's proprietary technology. ✅ Read Full Press Release: https://lnkd.in/dVgftmEX Visit our website to learn more: https://lnkd.in/dqgVFqDP #biomanufacturing #innovation #collaboration